Analysis of malignant melanoma risk and outcomes in solid organ transplant recipients: Assessment of transplant candidacy and the potential role of checkpoint inhibitors

Malignant melanoma (MM) causes tremendous morbidity and mortality in the solid organ transplant population and may arise in three different clinical scenarios: (1) pretransplant melanoma; (2) de novo melanoma post transplantation and (3) donor-derived melanoma. This manuscript primarily addresses the first two scenarios with respect to the evaluation and management of pretransplant MM, consideration of transplant candidacy and the occurrence and management of de novo MM post transplantation. The authors outline current evidence describing risks associated with pre-transplant melanoma to support recently established expert opinion for transplant candidacy.

Automated summary

This article discusses three different clinical scenarios of malignant melanoma in solid organ transplant population, focusing primarily on the evaluation and management of pretransplant melanoma, consideration of transplant candidacy, and the occurrence and management of de novo melanoma post transplantation. The authors outline current evidence on risks associated with pre-transplant melanoma to support recently established expert opinion for transplant candidacy.